Notably, genetic polymorphism of TM6SF2 in the dominant model was independently linked to the risk of developing NAFLD, and PNPLA3 genetic variants additively increased vulnerability to NAFLD‐related hepatic fibrosis. The gene discussed is TM6SF2; the disease is metabolic dysfunction-associated steatotic liver disease.